Want to join the conversation?
$VRTX expects Orkambi net product revenues to increase in 2016 as compared to 2015 as it recognizes revenues over a full fiscal year. $VRTX believes that Orkambi revenues in 2016, will be dependent on: total eligible patients, rate at which additional patients initiate treatment, proportion of initiated patients, and compliance rate for patients.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?